Research Analysts Issue Forecasts for MAZE FY2025 Earnings

Key Points

• Wedbush analysts have revised their FY2025 earnings estimate for Maze Therapeutics to ($3.37) per share, slightly improving from the previous forecast of ($3.39), maintaining an "Outperform" rating with a $17.00 target price.
• Maze Therapeutics reported a quarterly EPS of ($0.77), exceeding the consensus estimate of ($0.79) by $0.02, indicating better-than-expected performance.
• Investment firms are showing strong interest, with several analysts rating the stock as "buy," including a recent initiation by HC Wainwright at a $34.00 target price.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Investment analysts at Wedbush increased their FY2025 earnings per share (EPS) estimates for Maze Therapeutics in a report released on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($3.37) per share for the year, up from their previous forecast of ($3.39). Wedbush currently has a "Outperform" rating and a $17.00 target price on the stock. Wedbush also issued estimates for Maze Therapeutics' Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.70) EPS and FY2029 earnings at ($2.83) EPS.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Separately, HC Wainwright started coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and an average price target of $25.60.

Maze Therapeutics Price Performance

Shares of MAZE stock traded down $0.24 on Friday, hitting $13.11. 6,862 shares of the stock were exchanged, compared to its average volume of 199,550. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $19.19. The business has a 50-day moving average of $13.92.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund bought a new stake in Maze Therapeutics in the first quarter valued at approximately $25,000. CWM LLC acquired a new position in shares of Maze Therapeutics in the second quarter valued at approximately $28,000. Corebridge Financial Inc. acquired a new position in shares of Maze Therapeutics in the first quarter valued at approximately $48,000. Legal & General Group Plc grew its position in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after purchasing an additional 3,371 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Maze Therapeutics in the first quarter valued at approximately $57,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.